Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.

Cosman F, Nieves JW, Zion M, Garrett P, Neubort S, Dempster D, Lindsay R

The Journal of clinical endocrinology and metabolism11 May 2015Cited by 30 (Europe PMC)

PMID25961136PMCIDPMC5393523DOI10.1210/jc.2015-1715PepBankPUB-25961136

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study34

34 results from studies that gave the peptide. 34 results from people.

01HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, daily teriparatide increased lumbar spine BMD more than cyclic teriparatide.
In plain wordsIn previously untreated women with osteoporosis, daily teriparatide increased lower spine bone density more than cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD in treatment-naive women
Study
n = 86
Comparator
Cyclic teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · daily for 24 months versus four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
8.8%
daily, treatment-naive
BMD change
4.8%
cyclic, treatment-naive
Source sentences
Summary
Increases were 2-fold greater in daily vs cyclic groups (LS, 8.8 vs 4.8%; TH, 4.0 vs 2.1%; Troch, 5.6 vs 3.1%; and FN, 2.9 vs 1.2%; group differences, all P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
In Rx-naive women, BMD increased in the lumbar spine (LS), total hip (TH), trochanter (Troch), and femoral neck (FN) in daily and cyclic groups (within groups, P < .0002, except cyclic FN, P = .13).
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113621
02HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, daily teriparatide increased total hip BMD more than cyclic teriparatide.
In plain wordsIn previously untreated women with osteoporosis, daily teriparatide increased hip bone density more than cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD in treatment-naive women
Study
n = 86
Comparator
Cyclic teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · daily for 24 months versus four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
4%
daily, treatment-naive
BMD change
2.1%
cyclic, treatment-naive
Source sentences
Summary
Increases were 2-fold greater in daily vs cyclic groups (LS, 8.8 vs 4.8%; TH, 4.0 vs 2.1%; Troch, 5.6 vs 3.1%; and FN, 2.9 vs 1.2%; group differences, all P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
In Rx-naive women, BMD increased in the lumbar spine (LS), total hip (TH), trochanter (Troch), and femoral neck (FN) in daily and cyclic groups (within groups, P < .0002, except cyclic FN, P = .13).
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113622
03HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, daily teriparatide increased trochanter BMD more than cyclic teriparatide.
In plain wordsIn previously untreated women with osteoporosis, daily teriparatide increased trochanter bone density more than cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrochanter BMD in treatment-naive women
Study
n = 86
Comparator
Cyclic teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · daily for 24 months versus four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
5.6%
daily, treatment-naive
BMD change
3.1%
cyclic, treatment-naive
Source sentences
Summary
Increases were 2-fold greater in daily vs cyclic groups (LS, 8.8 vs 4.8%; TH, 4.0 vs 2.1%; Troch, 5.6 vs 3.1%; and FN, 2.9 vs 1.2%; group differences, all P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
In Rx-naive women, BMD increased in the lumbar spine (LS), total hip (TH), trochanter (Troch), and femoral neck (FN) in daily and cyclic groups (within groups, P < .0002, except cyclic FN, P = .13).
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113623
04HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, daily teriparatide increased femoral neck BMD more than cyclic teriparatide.
In plain wordsIn previously untreated women with osteoporosis, daily teriparatide increased thighbone neck density more than cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD in treatment-naive women
Study
n = 86
Comparator
Cyclic teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · daily for 24 months versus four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
2.9%
daily, treatment-naive
BMD change
1.2%
cyclic, treatment-naive
Source sentences
Summary
Increases were 2-fold greater in daily vs cyclic groups (LS, 8.8 vs 4.8%; TH, 4.0 vs 2.1%; Troch, 5.6 vs 3.1%; and FN, 2.9 vs 1.2%; group differences, all P < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
In Rx-naive women, BMD increased in the lumbar spine (LS), total hip (TH), trochanter (Troch), and femoral neck (FN) in daily and cyclic groups (within groups, P < .0002, except cyclic FN, P = .13).
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113624
05HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, radius BMD fell with both schedules without a significant difference between daily and cyclic teriparatide.
In plain wordsIn previously untreated women with osteoporosis, forearm bone density fell with both schedules without a significant difference between daily and cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeRadius BMD in treatment-naive women
Study
n = 86
Comparator
Cyclic teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · daily for 24 months versus four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
Radius BMD change
−4.2%
daily
Radius BMD change
−2.1%
cyclic
Source sentences
Summary
In daily vs cyclic groups, radius BMD declined (-4.2 vs -2.1%, respectively; both P < .01; group difference, P = .08) and total bone mineral increased modestly (1.4%, P = .18; vs 1.5%, P = .06; group difference, not significant).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113625
06HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, total bone mineral did not differ significantly between daily and cyclic teriparatide.
In plain wordsIn previously untreated women with osteoporosis, total bone mineral did not differ significantly between daily and cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal bone mineral in treatment-naive women
Study
n = 86
Comparator
Cyclic teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · daily for 24 months versus four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
Total bone mineral change
1.4%
daily
Total bone mineral change
1.5%
cyclic
Source sentences
Summary
In daily vs cyclic groups, radius BMD declined (-4.2 vs -2.1%, respectively; both P < .01; group difference, P = .08) and total bone mineral increased modestly (1.4%, P = .18; vs 1.5%, P = .06; group difference, not significant).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113626
07HumanRandomized controlled trialEfficacy outcome
In alendronate-treated women with osteoporosis, lumbar spine BMD increased without a significant difference between daily and cyclic teriparatide.
In plain wordsIn alendronate-treated women with osteoporosis, lumbar spine bone density increased without a significant difference between daily and cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeLumbar spine BMD in alendronate-treated women
Study
n = 64
Comparator
Cyclic teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · daily for 24 months versus four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
7.5%
daily, ALN-Rx
BMD change
6%
cyclic, ALN-Rx
Source sentences
Summary
In ALN-Rx women, there were no group differences (daily vs cyclic: LS, 7.5 and 6.0%; TH, 3 and 2.5%; Troch, 3.7 and 3.3%; FN, 3 and 1.5%; within groups, P < .003; except cyclic FN, P = .2).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113627
08HumanRandomized controlled trialEfficacy outcome
In alendronate-treated women with osteoporosis, total hip BMD increased without a significant difference between daily and cyclic teriparatide.
In plain wordsIn alendronate-treated women with osteoporosis, total hip bone density increased without a significant difference between daily and cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal hip BMD in alendronate-treated women
Study
n = 64
Comparator
Cyclic teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · daily for 24 months versus four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
3%
daily, ALN-Rx
BMD change
2.5%
cyclic, ALN-Rx
Source sentences
Summary
In ALN-Rx women, there were no group differences (daily vs cyclic: LS, 7.5 and 6.0%; TH, 3 and 2.5%; Troch, 3.7 and 3.3%; FN, 3 and 1.5%; within groups, P < .003; except cyclic FN, P = .2).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113628
09HumanRandomized controlled trialEfficacy outcome
In alendronate-treated women with osteoporosis, trochanter BMD increased without a significant difference between daily and cyclic teriparatide.
In plain wordsIn alendronate-treated women with osteoporosis, trochanter bone density increased without a significant difference between daily and cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTrochanter BMD in alendronate-treated women
Study
n = 64
Comparator
Cyclic teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · daily for 24 months versus four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
3.7%
daily, ALN-Rx
BMD change
3.3%
cyclic, ALN-Rx
Source sentences
Summary
In ALN-Rx women, there were no group differences (daily vs cyclic: LS, 7.5 and 6.0%; TH, 3 and 2.5%; Troch, 3.7 and 3.3%; FN, 3 and 1.5%; within groups, P < .003; except cyclic FN, P = .2).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113629
10HumanRandomized controlled trialEfficacy outcome
In alendronate-treated women with osteoporosis, femoral neck BMD did not differ significantly between daily and cyclic teriparatide.
In plain wordsIn women with osteoporosis receiving alendronate, thighbone neck density did not differ significantly between daily and cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD in alendronate-treated women
Study
n = 64
Comparator
Cyclic teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · daily for 24 months versus four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
3%
daily, ALN-Rx
BMD change
1.5%
cyclic, ALN-Rx
Source sentences
Summary
In ALN-Rx women, there were no group differences (daily vs cyclic: LS, 7.5 and 6.0%; TH, 3 and 2.5%; Troch, 3.7 and 3.3%; FN, 3 and 1.5%; within groups, P < .003; except cyclic FN, P = .2).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113630
11HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, daily teriparatide increased lumbar spine BMD from baseline.
In plain wordsIn previously untreated women with osteoporosis, lower spine density increased with daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD, daily, treatment-naive
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
BMD change
8.8%
daily, lumbar spine
Source sentences
Summary
In Rx-naive women, BMD increased in the lumbar spine (LS), total hip (TH), trochanter (Troch), and femoral neck (FN) in daily and cyclic groups (within groups, P < .0002, except cyclic FN, P = .13). Increases were 2-fold greater in daily vs cyclic groups (LS, 8.8 vs 4.8%; TH, 4.0 vs 2.1%; Troch, 5.6…
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113601
12HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, cyclic teriparatide increased lumbar spine BMD from baseline.
In plain wordsIn previously untreated women with osteoporosis, lower spine density increased with cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD, cyclic, treatment-naive
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
4.8%
cyclic, lumbar spine
Source sentences
Summary
In Rx-naive women, BMD increased in the lumbar spine (LS), total hip (TH), trochanter (Troch), and femoral neck (FN) in daily and cyclic groups (within groups, P < .0002, except cyclic FN, P = .13). Increases were 2-fold greater in daily vs cyclic groups (LS, 8.8 vs 4.8%; TH, 4.0 vs 2.1%; Troch, 5.6…
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113602
13HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, daily teriparatide increased total hip BMD from baseline.
In plain wordsIn previously untreated women with osteoporosis, hip density increased with daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD, daily, treatment-naive
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
BMD change
4%
daily, total hip
Source sentences
Summary
In Rx-naive women, BMD increased in the lumbar spine (LS), total hip (TH), trochanter (Troch), and femoral neck (FN) in daily and cyclic groups (within groups, P < .0002, except cyclic FN, P = .13). Increases were 2-fold greater in daily vs cyclic groups (LS, 8.8 vs 4.8%; TH, 4.0 vs 2.1%; Troch, 5.6…
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113603
14HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, cyclic teriparatide increased total hip BMD from baseline.
In plain wordsIn previously untreated women with osteoporosis, hip density increased with cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD, cyclic, treatment-naive
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
2.1%
cyclic, total hip
Source sentences
Summary
In Rx-naive women, BMD increased in the lumbar spine (LS), total hip (TH), trochanter (Troch), and femoral neck (FN) in daily and cyclic groups (within groups, P < .0002, except cyclic FN, P = .13). Increases were 2-fold greater in daily vs cyclic groups (LS, 8.8 vs 4.8%; TH, 4.0 vs 2.1%; Troch, 5.6…
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113604
15HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, daily teriparatide increased trochanter BMD from baseline.
In plain wordsIn previously untreated women with osteoporosis, trochanter density increased with daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrochanter BMD, daily, treatment-naive
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
BMD change
5.6%
daily, trochanter
Source sentences
Summary
In Rx-naive women, BMD increased in the lumbar spine (LS), total hip (TH), trochanter (Troch), and femoral neck (FN) in daily and cyclic groups (within groups, P < .0002, except cyclic FN, P = .13). Increases were 2-fold greater in daily vs cyclic groups (LS, 8.8 vs 4.8%; TH, 4.0 vs 2.1%; Troch, 5.6…
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113605
16HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, cyclic teriparatide increased trochanter BMD from baseline.
In plain wordsIn previously untreated women with osteoporosis, trochanter density increased with cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrochanter BMD, cyclic, treatment-naive
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
3.1%
cyclic, trochanter
Source sentences
Summary
In Rx-naive women, BMD increased in the lumbar spine (LS), total hip (TH), trochanter (Troch), and femoral neck (FN) in daily and cyclic groups (within groups, P < .0002, except cyclic FN, P = .13). Increases were 2-fold greater in daily vs cyclic groups (LS, 8.8 vs 4.8%; TH, 4.0 vs 2.1%; Troch, 5.6…
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113606
17HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, daily teriparatide increased femoral neck BMD from baseline.
In plain wordsIn previously untreated women with osteoporosis, thighbone neck density increased with daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD, daily, treatment-naive
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
BMD change
2.9%
daily, femoral neck
Source sentences
Summary
In Rx-naive women, BMD increased in the lumbar spine (LS), total hip (TH), trochanter (Troch), and femoral neck (FN) in daily and cyclic groups (within groups, P < .0002, except cyclic FN, P = .13). Increases were 2-fold greater in daily vs cyclic groups (LS, 8.8 vs 4.8%; TH, 4.0 vs 2.1%; Troch, 5.6…
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113607
18HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, femoral neck BMD did not increase significantly from baseline with cyclic teriparatide.
In plain wordsIn previously untreated women with osteoporosis, thighbone neck density did not increase significantly with cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD, cyclic, treatment-naive
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
1.2%
cyclic, femoral neck
Source sentences
Summary
In Rx-naive women, BMD increased in the lumbar spine (LS), total hip (TH), trochanter (Troch), and femoral neck (FN) in daily and cyclic groups (within groups, P < .0002, except cyclic FN, P = .13). Increases were 2-fold greater in daily vs cyclic groups (LS, 8.8 vs 4.8%; TH, 4.0 vs 2.1%; Troch, 5.6…
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113608
19HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, daily teriparatide decreased radius BMD from baseline.
In plain wordsIn previously untreated women with osteoporosis, forearm density decreased with daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseRadius BMD, daily, treatment-naive
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
BMD change
−4.2%
daily, radius
Source sentences
Summary
In daily vs cyclic groups, radius BMD declined (-4.2 vs -2.1%, respectively; both P < .01; group difference, P = .08) and total bone mineral increased modestly (1.4%, P = .18; vs 1.5%, P = .06; group difference, not significant).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113609
20HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, cyclic teriparatide decreased radius BMD from baseline.
In plain wordsIn previously untreated women with osteoporosis, forearm density decreased with cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseRadius BMD, cyclic, treatment-naive
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
−2.1%
cyclic, radius
Source sentences
Summary
In daily vs cyclic groups, radius BMD declined (-4.2 vs -2.1%, respectively; both P < .01; group difference, P = .08) and total bone mineral increased modestly (1.4%, P = .18; vs 1.5%, P = .06; group difference, not significant).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113610
21HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, total bone mineral did not increase significantly from baseline with daily teriparatide.
In plain wordsIn previously untreated women with osteoporosis, total bone mineral did not increase significantly with daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal bone mineral, daily, treatment-naive
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Total bone mineral change
1.4%
daily
Source sentences
Summary
In daily vs cyclic groups, radius BMD declined (-4.2 vs -2.1%, respectively; both P < .01; group difference, P = .08) and total bone mineral increased modestly (1.4%, P = .18; vs 1.5%, P = .06; group difference, not significant).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113611
22HumanRandomized controlled trialEfficacy outcome
In treatment-naive women with osteoporosis, total bone mineral did not increase significantly from baseline with cyclic teriparatide.
In plain wordsIn previously untreated women with osteoporosis, total bone mineral did not increase significantly with cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal bone mineral, cyclic, treatment-naive
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
Total bone mineral change
1.5%
cyclic
Source sentences
Summary
In daily vs cyclic groups, radius BMD declined (-4.2 vs -2.1%, respectively; both P < .01; group difference, P = .08) and total bone mineral increased modestly (1.4%, P = .18; vs 1.5%, P = .06; group difference, not significant).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113612
23HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis on alendronate, daily teriparatide increased lumbar spine BMD from baseline.
In plain wordsIn women with osteoporosis who also took alendronate, lower spine density increased with daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD, daily, alendronate-treated
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
BMD change
7.5%
daily, lumbar spine, ALN-Rx
Source sentences
Summary
In ALN-Rx women, there were no group differences (daily vs cyclic: LS, 7.5 and 6.0%; TH, 3 and 2.5%; Troch, 3.7 and 3.3%; FN, 3 and 1.5%; within groups, P < .003; except cyclic FN, P = .2).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113613
24HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis on alendronate, cyclic teriparatide increased lumbar spine BMD from baseline.
In plain wordsIn women with osteoporosis who also took alendronate, lower spine density increased with cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD, cyclic, alendronate-treated
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
6%
cyclic, lumbar spine, ALN-Rx
Source sentences
Summary
In ALN-Rx women, there were no group differences (daily vs cyclic: LS, 7.5 and 6.0%; TH, 3 and 2.5%; Troch, 3.7 and 3.3%; FN, 3 and 1.5%; within groups, P < .003; except cyclic FN, P = .2).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113614
25HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis on alendronate, daily teriparatide increased total hip BMD from baseline.
In plain wordsIn women with osteoporosis who also took alendronate, hip density increased with daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD, daily, alendronate-treated
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
BMD change
3%
daily, total hip, ALN-Rx
Source sentences
Summary
In ALN-Rx women, there were no group differences (daily vs cyclic: LS, 7.5 and 6.0%; TH, 3 and 2.5%; Troch, 3.7 and 3.3%; FN, 3 and 1.5%; within groups, P < .003; except cyclic FN, P = .2).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113615
26HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis on alendronate, cyclic teriparatide increased total hip BMD from baseline.
In plain wordsIn women with osteoporosis who also took alendronate, hip density increased with cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD, cyclic, alendronate-treated
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
2.5%
cyclic, total hip, ALN-Rx
Source sentences
Summary
In ALN-Rx women, there were no group differences (daily vs cyclic: LS, 7.5 and 6.0%; TH, 3 and 2.5%; Troch, 3.7 and 3.3%; FN, 3 and 1.5%; within groups, P < .003; except cyclic FN, P = .2).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113616
27HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis on alendronate, daily teriparatide increased trochanter BMD from baseline.
In plain wordsIn women with osteoporosis who also took alendronate, trochanter density increased with daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrochanter BMD, daily, alendronate-treated
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
BMD change
3.7%
daily, trochanter, ALN-Rx
Source sentences
Summary
In ALN-Rx women, there were no group differences (daily vs cyclic: LS, 7.5 and 6.0%; TH, 3 and 2.5%; Troch, 3.7 and 3.3%; FN, 3 and 1.5%; within groups, P < .003; except cyclic FN, P = .2).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113617
28HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis on alendronate, cyclic teriparatide increased trochanter BMD from baseline.
In plain wordsIn women with osteoporosis who also took alendronate, trochanter density increased with cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrochanter BMD, cyclic, alendronate-treated
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
3.3%
cyclic, trochanter, ALN-Rx
Source sentences
Summary
In ALN-Rx women, there were no group differences (daily vs cyclic: LS, 7.5 and 6.0%; TH, 3 and 2.5%; Troch, 3.7 and 3.3%; FN, 3 and 1.5%; within groups, P < .003; except cyclic FN, P = .2).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113618
29HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis on alendronate, daily teriparatide increased femoral neck BMD from baseline.
In plain wordsIn women with osteoporosis who also took alendronate, thighbone neck density increased with daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD, daily, alendronate-treated
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
BMD change
3%
daily, femoral neck, ALN-Rx
Source sentences
Summary
In ALN-Rx women, there were no group differences (daily vs cyclic: LS, 7.5 and 6.0%; TH, 3 and 2.5%; Troch, 3.7 and 3.3%; FN, 3 and 1.5%; within groups, P < .003; except cyclic FN, P = .2).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113619
30HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis on alendronate, femoral neck BMD did not increase significantly from baseline with cyclic teriparatide.
In plain wordsIn women with osteoporosis who also took alendronate, thighbone neck density did not increase significantly with cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD, cyclic, alendronate-treated
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
BMD change
1.5%
cyclic, femoral neck, ALN-Rx
Source sentences
Summary
In ALN-Rx women, there were no group differences (daily vs cyclic: LS, 7.5 and 6.0%; TH, 3 and 2.5%; Troch, 3.7 and 3.3%; FN, 3 and 1.5%; within groups, P < .003; except cyclic FN, P = .2).
2 context sentences(design, population, supporting numbers)
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113620
31HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis on alendronate, radius BMD did not change significantly from baseline with daily teriparatide.
In plain wordsIn women with osteoporosis who also took alendronate, forearm bone density did not change significantly with daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeRadius BMD with daily teriparatide in alendronate-treated women
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Radius BMD change
−0.7%
daily, ALN-Rx
Source sentences
Summary
In daily and cyclic groups, radius BMD decreased (-0.7% [not significant] and -1.4% [P < .05], respectively), and total bone mineral increased 2.3 and 3% (both P < .001).
3 context sentences(design, population, supporting numbers)
Summary · context
In ALN-Rx women, there were no group differences (daily vs cyclic: LS, 7.5 and 6.0%; TH, 3 and 2.5%; Troch, 3.7 and 3.3%; FN, 3 and 1.5%; within groups, P < .003; except cyclic FN, P = .2).
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113631
32HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis on alendronate, radius BMD decreased significantly from baseline with cyclic teriparatide.
In plain wordsIn women with osteoporosis who also took alendronate, forearm bone density decreased with cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseRadius BMD with cyclic teriparatide in alendronate-treated women
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · four 3-month cycles, each followed by 3 months off (12 months total teriparatide) within 24 monthsAs given in this study (human).
Measurements
Radius BMD change
−1.4%
cyclic, ALN-Rx
Source sentences
Summary
In daily and cyclic groups, radius BMD decreased (-0.7% [not significant] and -1.4% [P < .05], respectively), and total bone mineral increased 2.3 and 3% (both P < .001).
3 context sentences(design, population, supporting numbers)
Summary · context
In ALN-Rx women, there were no group differences (daily vs cyclic: LS, 7.5 and 6.0%; TH, 3 and 2.5%; Troch, 3.7 and 3.3%; FN, 3 and 1.5%; within groups, P < .003; except cyclic FN, P = .2).
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113632
33HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis on alendronate, total bone mineral increased by 2.3% from baseline with daily teriparatide.
In plain wordsIn women with osteoporosis who also took alendronate, total bone mineral increased with daily teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal bone mineral with daily teriparatide in alendronate-treated women
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 24 monthsAs given in this study (human).
Measurements
Total bone mineral change
2.3%
daily, ALN-Rx
Source sentences
Summary
In daily and cyclic groups, radius BMD decreased (-0.7% [not significant] and -1.4% [P < .05], respectively), and total bone mineral increased 2.3 and 3% (both P < .001).
3 context sentences(design, population, supporting numbers)
Summary · context
In ALN-Rx women, there were no group differences (daily vs cyclic: LS, 7.5 and 6.0%; TH, 3 and 2.5%; Troch, 3.7 and 3.3%; FN, 3 and 1.5%; within groups, P < .003; except cyclic FN, P = .2).
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113633
34HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis who remained on alendronate, total bone mineral increased by 3% in the group given cyclic teriparatide.
In plain wordsIn women with osteoporosis who stayed on alendronate, total bone mineral rose by 3% in the group given cyclic teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal bone mineral with cyclic teriparatide in alendronate-treated women
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · four 3-month cycles, each followed by 3 months off (12 months total teriparatide), over 24 monthsAs given in this study (human).
Measurements
Total bone mineral change
3%
cyclic, ALN-Rx
Source sentences
Summary
In daily and cyclic groups, radius BMD decreased (-0.7% [not significant] and -1.4% [P < .05], respectively), and total bone mineral increased 2.3 and 3% (both P < .001).
3 context sentences(design, population, supporting numbers)
Summary · context
In ALN-Rx women, there were no group differences (daily vs cyclic: LS, 7.5 and 6.0%; TH, 3 and 2.5%; Troch, 3.7 and 3.3%; FN, 3 and 1.5%; within groups, P < .003; except cyclic FN, P = .2).
Summary · context
Subjects participated in a randomized open-label study for 2 years.
Summary · context
Within cohorts, women were randomized to daily TPTD for 24 months or four 3-month TPTD cycles, each followed by 3 months off (12 mo total TPTD).
Report a problemFND-2596113634

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.